Status: Recruiting
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
The Phase 1 safety study of VOY-101 comprises of escalating dose Cohorts, followed by a Phase 2a.
Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 60+Biological sex: AllType: InterventionalSponsor: Perceive Biotherapeutics, Inc.Updated: Oct 15, 2025Locations: 11
Eligibility criteria
Are ≥60 years of age at the time of consent. [+7]
Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use... [+1]